和铂医药（上海）有限公司 Harbour BioMed Mediaroom

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed...

2026-03-09 16:32 3776

Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- Harbour BioMed ...

2026-02-04 08:01 7528

Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem

CAMBRIDGE, Mass., Jan. 28, 2026 /PRNewswire/ -- Recently, as a core co-founder and co-organizer, No...

2026-01-29 09:00 3798

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed...

2026-01-19 08:02 10468

Nona Biosciences Enters into Collaboration Agreement with Link Cell Therapies to Advance CAR-T Cell Therapies

CAMBRIDGE, Mass., Jan. 9, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology co...

2026-01-09 20:00 3317

Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed...

2025-12-29 09:58 3967

Nona Biosciences Expands Integrated Discovery-to-Clinical Capabilities Through Strategic Platform Growth

CAMBRIDGE, Mass., Dec. 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company ad...

2025-12-24 09:20 3292

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ -- Harbour BioMed...

2025-12-17 08:04 2105

Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery

CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global...

2025-12-04 10:01 2026

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed...

2025-11-24 08:01 1834

Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery

Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery ...

2025-11-19 20:08 1577

Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ...

2025-11-07 14:00 1737

Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies

CAMBRIDGE, Mass., Nov. 5, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company pro...

2025-11-05 20:07 1172

Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- Harbour BioMed...

2025-10-28 22:07 1388

Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth

CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a globa...

2025-10-15 08:00 1443

Harbour BioMed Reports 2025 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed...

2025-08-27 22:40 2411

Harbour BioMed Appoints Yajie Li as Chief Medical Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 24, 2025 /PRNewswire/ -- Harbour BioMed...

2025-08-25 09:00 2206

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed...

2025-07-30 08:01 2358

Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2025 /PRNewswire/ -- Harbour BioMed...

2025-07-28 08:11 2541

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

* Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patie...

2025-07-23 20:36 2353

Latest News